Investment Plan for Europe supports pharmaceutical company in Spain with €20 million

Daily News 26/01/2021

Economia - pubblicata il 28 Gennaio 2021

Source: European Commission Spokesperson’s Service

The European Investment Bank (EIB) will provide €20 million to finance the research, development and innovation programme of Galenicum, a pharmaceutical company founded in Barcelona, Spain.

The project is backed by a guarantee provided by the European Fund for Strategic Investments
, the main pillar of the Investment Plan for Europe. This financing will support the company’s development of medicines in various treatment areas such as diabetes, oncology and the
central nervous system. Furthermore, the financing will contribute to efforts to mitigate the effects of COVID-19 since Galenicum manufactures medicines widely used to treat the virus like
paracetamol (first line of treatment of symptoms) and metformin (essential treatment for diabetic patients, who are vulnerable to COVID-19).

Commissioner for the Economy, Paolo Gentiloni, said: Thanks to the Investment Plan for Europe, the EIB has signed a financing agreement with Spanish pharmaceutical
company Galenicum that manufactures drugs, including those used to treat the COVID-19 virus. The new funding will allow the company to expand its operations and portfolio of products and services
helping for instance patients affected by cancer and diabetes. This EU support comes at the right time when groundbreaking medical research is more important than ever.

Investment Plan for Europe
has so far mobilised €546 billion of investment across the EU, of which €63 billion in Spain.

The press release is available here.

Corsi e convegni


Economic Report


News Europa